ACIST RXi™ RAPID EXCHANGE FFR SYSTEM TO BE SHOWCASED
IN LIVE CASE TRANSMISSIONS AT EuroPCR
Physicians to Conduct Multi-Vessel PCI with ACIST Navvus™ Rapid Exchange MicroCatheter
EDEN PRAIRIE, Minn. (MAY 21, 2014) – ACIST Medical Systems, Inc., a Bracco Group company, pioneer and global market leader of advanced contrast delivery systems for cardiology, today announced that its new ACIST|RXi™ Rapid Exchange FFR System – the world’s first Rapid Exchange FFR system, will be presented in a live case of a complex multi-vessel Percutaneous Coronary Intervention (PCI) at EuroPCR. Dr. Nicolas van Mieghem and Dr. Roberto Diletti will conduct the procedure from Erasmus Medical Center, Rotterdam, The Netherlands, on May 23, 2014.
The live case will showcase the ultra-thin ACIST Navvus™ Rapid Exchange MicroCatheter and its ability to facilitate FFR measurements in complex multi-vessel disease. The Navvus MicroCatheter can be used over a standard 0.014 inch guidewire, providing the physician maximum control while maintaining wire position throughout the coronary procedure. The RXi system also facilitates rapid FFR assessments before, during and post-intervention, to quickly assess blockages that could require PCI. This unique technology is the first of its kind, providing the reassurance of accurate and reliable FFR measurements and the advantages of Rapid Exchange technology.
“With Navvus, I have the ability to use my own guidewire and keep its position throughout the procedure. Now, I no longer have an excuse for not routinely performing FFR,” said Dr. Nicolas van Meighem.
The ACIST Rapid FFR system also will be featured in a second live case transmission on May 22 at EuroPCR. The live demonstration will come from Institut Cardiovasculaire Paris Sud Massy (France) and feature RXi as a tool for rapid FFR measurement in daily routine. Each of these presentations showcases the evolution and advancement of technology developed by ACIST to simplify the complexities in the Cath Lab.
“The technology in the RXi Rapid Exchange FFR System overcomes many of the limitations of traditional pressure-wire systems,” said Tom Morizio, President and COO, ACIST Medical Systems. “With both of these live case demonstrations, we’re excited to show interventionalists how this system allows and leads to positive patient results. This new device and technology sets new standards in emerging cardiology and strengthens our commitment to finding game-changing diagnostic solutions.”
ACIST’s technology takes a unique approach from the existing wire-based technologies. In addition to being a Rapid Exchange catheter, the ACIST Rapid FFR system utilizes fiber-optic technology, resulting in greater signal stability and less potential for signal drift. The ultra-thin Navvus MicroCatheter features simple plug and play by not requiring calibration therefore saving time and increasing ease of use versus older FFR wire-base systems.
ACIST globally launched RXi at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, D.C. in April. The device received 510(k) FDA clearance for use in obtaining intravascular pressure measurements in the diagnosis and treatment of coronary and peripheral artery disease in January 2014. The company successfully conducted a clinical trial in New Zealand and is currently performing an additional study in Europe. The first successful human case featuring the new system in the United States took place in Minnesota in February 2014.
ACIST, a Bracco Group company, is a pioneer and global market leader of advanced contrast delivery systems for cardiology. By developing advanced diagnostic technologies that help simplify the complexities of the cardiac cath lab, it empowers clinicians and their teams in providing superior patient care. ACIST products are being used by cardiologists in more than 70 countries worldwide, and more than 15 million patients have benefited from a cardiovascular angiography procedure using an ACIST Contrast Delivery System.
ACIST is headquartered in Eden Prairie, Minn., with regional offices in Europe and Asia. A team of more than 300 people worldwide helps manage and support a portfolio of products and services that simplify and enhance contrast injection procedures. ACIST and its sister company, HLT — a medical device company dedicated to the development of transcatheter aortic valve technology — are part of the Bracco Group, an international leader in diagnostic imaging. Both companies share the same founder, president and COO and commitment to innovation in interventional cardiology. Together, they are setting new standards in the industry with the pursuit of emerging cardiology solutions, addressing clinical and physician needs to provide superior patient care.
To learn more about ACIST, visit www.acist.com.
About the Bracco Group
Bracco has headquarters in Milan, Italy, and was founded in 1927. It is active in the healthcare sector through Bracco Imaging (diagnostic imaging), Pharma (prescription and over the counter drugs), ACIST Medical Systems and HLT (cardiology) and the Centro Diagnostico Italiano diagnostic clinic. It has around 3,300 employees and annual total consolidated revenues of over 1.2 billion Euro. Bracco operates in more than 90 countries worldwide.
To learn more about Bracco Group, visit www.bracco.com.
Contact: Gina Jung
ACIST Medical Systems
Direct: 952 995 9306